Table 2.
Baseline characteristics of study patients
| Cohort/Class | Men/Women (n/n) | Median Age (yr) | Median eGFR (ml/min per 1.73 m2)a | Median HtTKV (ml/m)b | Family History of ADPKD—Yes/No/Unknown (n/n/n) | Genetic Analysis, n (%) | NMD, n (%) | PKD1, n (%) | PKD2, n (%) | Median Follow-Up SCrc (mg/dl) | Median Follow-Up (yr) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MTPC | |||||||||||
| 1 | 538 (218/320) | 44 (35–51) | 75 (45–97) | 668 (430–1234) | 430/71/37 | 308 (57)d | 20 (6)e | 239 (78)e | 49 (16)e | 6 (4–12) | 6 (4–10) |
| 2 | |||||||||||
| A | 36 (21/15) | 60 (50–71) | 67 (57–80) | 591 (476–1020) | 16/14/6 | 11 (31)d | 5 (45)d | 6 (55)e | 0 (0)e | 4 (2–8) | 6 (3–9) |
| B | 16 (7/9) | 62 (50–70) | 33 (21–50) | 351 (248–481) | 9/6/1 | 2 (13)d | 0 (0)d | 2 (100)e | 0 (0)e | 9 (2–14) | 8 (4–11) |
| CRISP | |||||||||||
| 1 | 173 (67/106) | 34 (25–40) | 94 (80–112) | 492 (356–744) | 139/11/23 | 171 (99)d | 14 (8)e | 133 (78)e | 24 (14)e | 5 (4–6) | 9 (8–10) |
| 2 | |||||||||||
| A | 3 (1/2) | 43 (38–46) | 52 (51–55) | 886 (754–1574) | 2/0/1 | 3 (100)d | 0 (0)d | 1 (33.3)e | 2 (66.7)e | 5 | 9 (8–9) |
| B | 1 (1/0) | 16 | 74 | 260 | 1/0/0 | 1 (100)d | 0 | 1 (100)e | 0 | 5 | 10 |
| Total | 767 (315/452) | 42 (15–80) | 78 (9–173) | 608 (141–6167) | 597/102/68 | 496 (65)d | 39 (8)e | 382 (77)e | 75 (15)e | 6 (2–49) | 7 (0.5–18) |
Medians are expressed with interquartile ranges in parentheses. NMD, no mutation detected; SCr, serum creatinine.
a
Estimated using Chronic Kidney Disease Epidemiology equation.
b
Calculated by ellipsoid formula.
c
Does not include baseline SCr.
d
Percentage is based on total number of patients for each class.
e
Percentage is based on patients with genetic analysis within each class.